Abbott Vascular's Xience Prime EES Evaluated in Long Coronary Lesions


June 11, 2018—Findings from the multicenter Longprime registry evaluating the performance of the Xience Prime everolimus-eluting stent (Abbott Vascular) in patients with long coronary lesions were published by José Francisco Díaz Fernández, MD, et al online in Catheterization and Cardiovascular Interventions.

As summarized Catheterization and Cardiovascular Interventions, the prospective, multicenter registry was composed of consecutive patients (age, 64.8 ± 11.2 years; 77% men; and 33% diabetics) in 29 tertiary hospitals with > 24-mm de novo lesions in vessels of 2.25 to 4 mm. The primary and secondary endpoints were major adverse cardiac events (MACEs), including cardiac death, myocardial infarction, and target lesion revascularization, as well as and stent thrombosis at 1, 12, and 24 months. Patients were on dual antiplatelet therapy for 12 months.

The study included a total of 610 patients with 705 long lesions (1.2 per patient). Lesion length was 34.59 ± 11.17 mm and vessel size 2.93 ± 0.41 mm. Stented length was 39.83 ± 14.08 mm (1.4 stents per lesion). Pre- and postdilatation were performed in 75% and 33% of the cases, respectively. Intravascular ultrasound was performed in 15% of cases.

The investigators reported that the device success rate was 99.1%. MACE and stent thrombosis rates at 1, 12, and 24 months were 0.3%, 2.1%, and 5.4% and 0.2%, 0.7%, and 1.5%, respectively.

In this real‐world population, the Xience Prime EES performed extremely well in long lesions, with a very low rate of both MACE and stent thrombosis, concluded the investigators in Catheterization and Cardiovascular Interventions.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.